Jimini Health Raises $17M to Bring Clinician Oversight to AI in Behavioral Care

As artificial intelligence becomes more embedded in daily life, one of its most sensitive applications, mental health support, has been evolving largely outside traditional healthcare systems. Jimini Health is working to bring structure and oversight to that shift.

The New York based company has raised $17 million in seed funding, bringing its total funding to more than $25 million. The round includes backing from M13, Town Hall Ventures, LionBird, Zetta Venture Partners, and OneMind, reflecting growing investor attention on infrastructure designed for clinical AI deployment.

A Shift Healthcare Systems Can No Longer Ignore

The company is building against a backdrop where patient behavior has already changed. Millions of people are now using AI tools for mental health support between clinical visits, often without any involvement from healthcare providers.

For behavioral health systems, this creates a growing blind spot. Patients are engaging with tools that were not designed for clinical use, while providers remain responsible for outcomes without having visibility into those interactions. This disconnect introduces clinical risk, legal exposure, and operational challenges that existing systems were never built to manage.

At the same time, regulatory momentum is accelerating. Initiatives from agencies such as Centers for Medicare & Medicaid Services and the U.S. Food and Drug Administration are beginning to establish clearer pathways for AI enabled care, signaling that structured, clinician supervised solutions will be necessary for adoption at scale.

Sage: AI Designed as Part of the Care Team

At the center of Jimini’s platform is Sage, a patient facing AI system designed specifically for deployment inside large clinical organizations rather than as a standalone consumer tool.

The system is structured so that clinicians remain fully in control. Every patient interaction is visible to supervising professionals, and the AI operates within predefined care plans rather than generating open ended responses. This ensures that diagnostics and care decisions continue to sit with licensed clinicians, while the AI supports ongoing engagement between sessions.

The platform is also designed to operate across a wide range of patient needs, from lower acuity support to more complex clinical scenarios, while maintaining strict compliance with federal and state regulations.

Built for Real World Clinical Environments

A key part of Jimini’s approach is that it has been developed with real clinical deployment in mind from the start. The company has worked with advisors from leading institutions including Harvard, Stanford, Yale, Dartmouth, and Google DeepMind to shape its safety frameworks.

Unlike many AI platforms, Jimini also operates its own clinic, employing licensed clinicians who treat real patients using the system. This allows the company to evaluate model performance against actual clinical outcomes before rolling out updates more broadly.

The platform is also designed to integrate with existing healthcare infrastructure, including electronic health record systems, and to align with emerging reimbursement models as payers begin to support AI assisted care.

Expanding Across Clinical Partners

With the new funding, Jimini plans to expand its work with large behavioral health provider organizations across the United States. The company is focusing on extending Sage’s capabilities across additional care settings, comorbid conditions, and patient engagement formats.

It is also developing structured implementation pathways for healthcare systems, including clinician training, workflow integration, and customization based on specific organizational needs. The goal is to enable large, multi site providers to adopt AI in a way that fits within their existing care delivery models rather than requiring a complete redesign.

A Team Built for Regulated AI

Jimini’s founding team brings experience from both healthcare and AI driven companies operating in highly regulated environments. CEO Luis Voloch previously co founded Immunai, while other leaders have held seniors at companies such as Guardant Health, Ribbon Health, and Talkspace.

The company’s clinical and scientific leadership includes experts in psychiatry, digital therapeutics, and AI safety, with research contributions published in leading scientific journals. This combination reflects the complexity of building systems that must meet both technological and clinical standards.

Defining the Next Phase of AI in Mental Health

The broader shift taking place in behavioral health is moving beyond experimentation with AI tools toward structured integration within care systems.

As demand for mental health services continues to outpace provider capacity, AI is increasingly viewed as part of the solution. However, its long term will depend on whether it can be deployed in a way that is safe, accountable, and aligned with clinical practice.

Jimini’s approach highlights an emerging category focused not on replacing clinicians, but on building the infrastructure that allows AI to operate responsibly within healthcare.